FDAnews Announces — FDA’s Guidance on Drugs and Biologics During COVID-19 Webinar Oct. 20, 2020

Share Article

Keeping up with the FDA’s flurry of coronavirus related guidance on drug development, cGMP and inspections? Here’s how to comply.

WCG FDAnews

WCG FDAnews

FDA’s Guidance on Drugs and Biologics During COVID-19:
The Most Consequential Guidance Documents on Drug Development, cGMP & Inspections
An FDAnews Webinar
Tuesday, Oct. 20, 2020, 1:30 p.m.-3:00 p.m. EDT
https://www.fdanews.com/drugsbiologicscovid19

Complying with the more than 50 recent FDA guidance documents that govern drug development and manufacturing safety related to the coronavirus, COVID-19? If not, one risks serious delays bringing much needed preventative and therapeutic drugs to market.

This is the opportunity to get a handle on the most critical guidance documents on drug development methods, good manufacturing practices (GMPs) and FDA procedures.

In this webinar, consultant Keith Webber, Ph.D. will share the FDA’s most important coronavirus-related guidance one must adhere to if one wants to remain compliant. He has an insider’s understanding of where the agency is coming from, having spent 18 years in high-level positions within it, including as director of the Office of Pharmaceutical Science.

Dr. Webber will make sense of the flurry of guidances released, revealing how to:

  • Comply with supply chain drug and biologics inspections
  • Comply with exemptions from supply chain security
  • Comply with GMP manufacturing considerations
  • Comply with guidance on COVID-19 drugs (for treatment or prevention)
  • Comply with vaccine guidance (development and licensure)

Focus on the most-important COVID-19 related guidance addressing drug development, cGMPs and inspections. Or your products and processes will fall short.

Interested in registering multiple sites?
Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally
to learn about our special multisite discount.

Webinar Details:
FDA’s Guidance on Drugs and Biologics During COVID-19:
The Most Consequential Guidance Documents on Drug Development, cGMP & Inspections
An FDAnews Webinar
Tuesday, Oct. 20, 2020, 1:30 p.m.-3:00 p.m. EDT
https://www.fdanews.com/drugsbiologicscovid19

Tuition:
$287 per site

Easy Ways to Register:
Online: https://www.fdanews.com/drugsbiologicscovid19
By phone: 888.838.5578 or 703.538.7600

About FDAnews:
FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michelle Butler
FDAnews
703.538.7600
Email >
Visit website